Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

(2011) J. Tabernero et al.   CLINICAL CANCER RESEARCH

Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia

(2011) Jana Hof et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

(2011) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma

(2010) K. I. Pishas et al.   CLINICAL CANCER RESEARCH

The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

(2010) K. Kojima et al.   MOLECULAR CANCER THERAPEUTICS

Guidelines for accurate EC50/IC50 estimation

(2010) J. L. Sebaugh   PHARMACEUTICAL STATISTICS

Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis

(2009) T Van Maerken et al.   CELL DEATH AND DIFFERENTIATION

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

(2009) M. Miyachi et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

(2008) J A McCubrey et al.   LEUKEMIA

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER